Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Long-Term Investments: 2021-2025

Historic Long-Term Investments for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $133.1 million.

  • Krystal Biotech's Long-Term Investments rose 25.71% to $133.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.1 million, marking a year-over-year increase of 25.71%. This contributed to the annual value of $152.1 million for FY2024, which is 145.53% up from last year.
  • As of Q3 2025, Krystal Biotech's Long-Term Investments stood at $133.1 million, which was down 4.10% from $138.8 million recorded in Q2 2025.
  • Krystal Biotech's Long-Term Investments' 5-year high stood at $152.1 million during Q4 2024, with a 5-year trough of $4.6 million in Q4 2022.
  • Moreover, its 3-year median value for Long-Term Investments was $84.0 million (2024), whereas its average is $87.6 million.
  • As far as peak fluctuations go, Krystal Biotech's Long-Term Investments tumbled by 92.82% in 2022, and later soared by 1,537.67% in 2024.
  • Krystal Biotech's Long-Term Investments (Quarterly) stood at $64.4 million in 2021, then slumped by 92.82% to $4.6 million in 2022, then soared by 1,240.71% to $62.0 million in 2023, then spiked by 145.53% to $152.1 million in 2024, then increased by 25.71% to $133.1 million in 2025.
  • Its last three reported values are $133.1 million in Q3 2025, $138.8 million for Q2 2025, and $148.5 million during Q1 2025.